FEELM Shares the Honor With Clients at This Year’s Vapouround Awards, Winning Across Four Categories
17.5.2023 09:06:00 EEST | Business Wire | Press release
FEELM, the world’s leading closed system solution provider, belonging to SMOORE – a global leader in atomisation technology solutions – recently shone at the Vapouround 2023 annual awards ceremony in Birmingham last Friday, winning the Outstanding Contribution to the Vape Industry, and Best Manufacturer. Its client KIWI Go and DejaVoo Cyber also share the honor and won the first and second place of the “Best Disposable” categories respectively.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516006108/en/
(Graphic: Business Wire)
The Vapouround Awards are one of the most prestigious and authoritative annual awards for the global vaping industry. All winning brands are selected by a panel of professional judges and represent the outstanding performance of the past year in various segments of the industry. FEELM is not new to winning in the Vapouround Awards, with the brand having been awarded Industry Leader and Best Innovation in 2020.
FEELM has made notable achievements in the closed pod system category, with around 3.5 million pods sold to more than 50 countries since 2018. Its disposable ceramic coil technologies have also already been launched in key markets including France, the UK, and Belgium, and will soon be available more widely in more countries.
FEELM has been dedicated to embracing innovations with the aim of taking the industry standard to new heights. While most of the 2ml e-liquid disposable products provide only 600 puffs, FEELM Max solutions can now deliver 800 puffs, all whilst remaining TPD-compliant.
At the Birmingham Vaper Expo, on the Saturday at its launch event, FEELM unveiled its new innovative disposable solution, FEELM Max, with the advanced heating technology of its S1 ceramic coil. FEELM Max offers more puffs, greater taste consistency, and a fully visible mouthpiece to measure e-liquid, making it the best disposable available whilst still ensuring regulatory compliance with the Tobacco and Related Products Regulations (TRPR) in the UK and the Tobacco Products Directive (TPD) in the EU.
FEELM Max is now available in markets including the UK, Italy and Germany, and have been well-received by consumers, who have said that it feels silkier and smoother than other products.
We look forward to continuing to bring our FEELM Max technology to more consumers, whilst ensuring that our solutions are always compliant with the regulatory requirements where they are sold.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516006108/en/
Contact information
Claudia Liu
86 13974468623
mengmeng.liu@smooretech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom